Toll Free: 1-888-928-9744

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2016

Published: Apr 13, 2016 | Pages: 59 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2016', provides an overview of the Proliferative Diabetic Retinopathy (PDR) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR)
- The report reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Proliferative Diabetic Retinopathy (PDR) therapeutics and enlists all their major and minor projects
- The report assesses Proliferative Diabetic Retinopathy (PDR) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR)

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Content
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Proliferative Diabetic Retinopathy (PDR) Overview 6 Therapeutics Development 7 Pipeline Products for Proliferative Diabetic Retinopathy (PDR) - Overview 7 Proliferative Diabetic Retinopathy (PDR) - Therapeutics under Development by Companies 8 Proliferative Diabetic Retinopathy (PDR) - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Proliferative Diabetic Retinopathy (PDR) - Products under Development by Companies 11 Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development 12 Antisense Therapeutics Limited 12 Icon Bioscience, Inc. 13 Ohr Pharmaceutical Inc. 14 PanOptica, Inc. 15 Ribomic Inc. 16 Sirnaomics, Inc. 17 ThromboGenics NV 18 Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 ATL-1103 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 cyclosporine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ocriplasmin (recombinant) - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 OLX-302 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 PAN-90806 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 RBM-008 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 squalamine lactate - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 STP-601 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Proliferative Diabetic Retinopathy (PDR) - Recent Pipeline Updates 42 Proliferative Diabetic Retinopathy (PDR) - Dormant Projects 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Antisense Therapeutics Limited, H1 2016 12 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Icon Bioscience, Inc., H1 2016 13 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ohr Pharmaceutical Inc., H1 2016 14 Proliferative Diabetic Retinopathy (PDR) - Pipeline by PanOptica, Inc., H1 2016 15 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ribomic Inc., H1 2016 16 Proliferative Diabetic Retinopathy (PDR) - Pipeline by Sirnaomics, Inc., H1 2016 17 Proliferative Diabetic Retinopathy (PDR) - Pipeline by ThromboGenics NV, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Proliferative Diabetic Retinopathy (PDR) Therapeutics - Recent Pipeline Updates, H1 2016 42 Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H1 2016 57


List of Figures
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Top 10 Targets, H1 2016 20 Number of Products by Stage and Top 10 Targets, H1 2016 20 Number of Products by Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify